What’s New and Updates/Changes

What’s New and Updates/Changes
Thursday, April 27, 2017

This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance. 

Global Changes Occurring throughout the document:

  • RAV changed to RAS
  • Standardized renal function parameter from CrCI to eGFR
     

Initial Treatment:

Retreatment:

Decompensated:

Renal:

Upcoming Updates:

  • Guidance will be forthcoming regarding treatment of adolescents living with chronic HCV given recent FDA-approvals
What’s New and Updates/Changes
Friday, September 16, 2016

The HCV Guidance Panel has reviewed new information that highlights the risk of HBV infection reactivation in patients who are coinfected and who clear HCV with DAAs. They have therefore chosen to alert providers. The updated information can be found in the Monitoring Patients Who Are Starting Hepatitis C Treatment, Are On Treatment, or Have Completed Therapy section of the Guidance.

Click here to read the press release.
 

What’s New and Updates/Changes
Wednesday, July 6, 2016

This version of the Guidance has been updated to reflect several important developments, including the recent approval of sofosbuvir/velpatasvir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

Other updates reflecting recent data are provided in:

Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:

Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:

Updated references have been provided throughout the Guidance.

What’s New and Updates/Changes:
Wednesday, February 24, 2016

This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

Other updates reflecting recent data are provided in:

Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:

Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:

Updated references have been provided throughout the Guidance.

Guidance Sections Updated
Friday, December 11, 2015

In the Initial, Retreatment, and Monitoring sections, recommendations regarding the use of paritaprevir/ritonavir/ombitasvir plus dasabuvir in those with advanced liver disease have been revised based on an FDA warning issued on October 22, 2015.

Pages